SGCG and Myocardial fibrosis: A recent study by Zile et al. documented that S/V decreased some biomarkers of profibrotic signaling (aldosterone, Soluble Isoform of ST2, Tissue Inhibitor of Metalloproteinase-1, Galectin-3 Protein, Procollagen Type I N-propeptide, and Type III Procollagen Peptide in HFrEF patients, thus suggesting that S/V may reduce myocardial fibrosis and improve clinical outcomes.